<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814498</url>
  </required_header>
  <id_info>
    <org_study_id>B-0409-103</org_study_id>
    <nct_id>NCT04814498</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction (DDI) Study in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single&#xD;
      Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy&#xD;
      Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open label study designed to determine the effect of BLD-0409 on the&#xD;
      PK of probe substrates and to evaluate the safety and tolerability of BLD-0409 administered&#xD;
      alone and co-administered with a cocktail of probe substrates (i.e., Geneva cocktail less&#xD;
      fexofenadine) in healthy adult volunteers.&#xD;
&#xD;
      Geneva Cocktail (Less Fexofenadine):&#xD;
&#xD;
        -  CYP1A2 Caffeine 50 mg&#xD;
&#xD;
        -  CYP2C Flurbiprofen 10 mg&#xD;
&#xD;
        -  CYP2C19 Omeprazole 10 mg&#xD;
&#xD;
        -  CYP2D6 Dextromethorphan 10 mg&#xD;
&#xD;
        -  CYP3A4 Midazolam 1 mg&#xD;
&#xD;
        -  CYP2B6 Bupropion 20 mg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to the last measurable concentration (AUC0-last)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Measured by plasma concentration of probe substrates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Measured by plasma concentration of probe substrates</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Drug Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Geneva cocktail (less fexofenadine) &amp; BLD-0409</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast of at least 10 hours, subjects will be administered IP in a fixed sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geneva Cocktail</intervention_name>
    <description>Fixed sequence use of drug cocktail</description>
    <arm_group_label>Geneva cocktail (less fexofenadine) &amp; BLD-0409</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-0409</intervention_name>
    <description>Fixed sequence use of active product</description>
    <arm_group_label>Geneva cocktail (less fexofenadine) &amp; BLD-0409</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed informed consent prior to study entry.&#xD;
&#xD;
          2. Males and females aged 18 to 55 years at the time of consent.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2.&#xD;
&#xD;
          4. Agree to abstain from alcohol intake from 48 hours before first IP administration&#xD;
             through to discharge from the CRU.&#xD;
&#xD;
          5. Agree to abstain from all caffeine- and xanthine-containing products (e.g., coffee,&#xD;
             tea, cola drinks, chocolate) for 48 hours before first IP administration through to&#xD;
             discharge from the CRU.&#xD;
&#xD;
          6. Have a negative urine drug screen/alcohol breath test at Day -1 (Admission). Repeat&#xD;
             urine drug screens will be permitted for suspected false positive results.&#xD;
&#xD;
          7. Use of acceptable contraception.&#xD;
&#xD;
          8. Males must not donate sperm for at least 90 days after the last dose of study drug.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine or serum pregnancy test on Day -1. If a urine test is&#xD;
             conducted and it is positive, a serum pregnancy test must also be performed for&#xD;
             confirmation. Females not of childbearing potential must be postmenopausal (defined as&#xD;
             cessation of regular menstrual periods for at least 12 months), confirmed by&#xD;
             follicle-stimulating hormone (FSH) level &gt; 40 mIU/mL at Screening.&#xD;
&#xD;
         10. In good general health, in the opinion of the Principal Investigator (PI), with no&#xD;
             significant medical history, have no clinically significant abnormalities on physical&#xD;
             examination at Screening, and/or before administration of the initial dose of study&#xD;
             drug.&#xD;
&#xD;
         11. Have clinical laboratory values within normal ranges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active smoker and/or user of nicotine-containing products (i.e., have not used&#xD;
             nicotine-containing products within the previous 3 months).&#xD;
&#xD;
          2. Human immunodeficiency virus (HIV) antibody positive.&#xD;
&#xD;
          3. Hepatitis B surface antigen (HBsAg) positive or Hepatitis C virus (HCV) positive.&#xD;
&#xD;
          4. Presence of any underlying or clinically significant physical or psychological medical&#xD;
             condition (e.g., hypertension, elevated cholesterol/triglycerides, asthma, or&#xD;
             diabetes) that, in the opinion of the PI, would make it unlikely that the subject will&#xD;
             complete the study per protocol.&#xD;
&#xD;
          5. History or presence of alcohol or drug abuse (including recreational marijuana use)&#xD;
             within the 2 years prior to the first IP administration, and unwillingness to be&#xD;
             totally abstinent during the period of confinement.&#xD;
&#xD;
          6. Blood donation or significant blood loss within 30 days prior to the first study drug&#xD;
             administration.&#xD;
&#xD;
          7. Plasma donation within 7 days prior to the first study drug administration.&#xD;
&#xD;
          8. Administration of IP in another trial within 30 days prior to the first IP&#xD;
             administration, or 5 half-lives, whichever is longer.&#xD;
&#xD;
          9. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         10. Surgery within the past 3 months prior to the first IP administration determined by&#xD;
             the PI to be clinically relevant.&#xD;
&#xD;
         11. Consumption of any nutrients known to modulate cytochrome P450 3A4 (CYP3A4) or any&#xD;
             strong inhibitors or inducers of CYP3A4, starting from 14 days prior to the first dose&#xD;
             of IP on Day 1 and until the EOS assessments.&#xD;
&#xD;
         12. Consumption of cruciferous vegetables or chargrilled meat more than 3 × per week in&#xD;
             the previous 2 weeks.&#xD;
&#xD;
         13. Inability to refrain from consumption of grapefruit and Seville oranges or St. John's&#xD;
             Wort within 14 days prior to the first dose of IP on Day 1 and until the EOS&#xD;
             assessments.&#xD;
&#xD;
         14. Failure to satisfy the PI of fitness to participate for any other reason.&#xD;
&#xD;
         15. Active infection (diagnosed or suspected) or history of recurrent infections.&#xD;
&#xD;
         16. Active malignancy and/or history of malignancy in the past 5 years, except for&#xD;
             completely excised non-melanoma skin carcinomas or low grade cervical intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
         17. Serious local infection or systemic infection within 3 months requiring antibiotic&#xD;
             treatment.&#xD;
&#xD;
         18. Any acute illness within 30 days prior to Day 1.&#xD;
&#xD;
         19. Use of any prescription or over-the-counter (OTC) medication (except for paracetamol&#xD;
             and approved contraceptives) within 5 days or 5 half-lives (whichever is longer) prior&#xD;
             to dosing and during course of study without prior approval of the Investigator and&#xD;
             Medical Monitor. Simple analgesia (paracetamol) may be permitted at the discretion of&#xD;
             the Investigator.&#xD;
&#xD;
         20. For all participants, the use of any estrogen-containing products (e.g.,&#xD;
             contraceptives, patch, cream, implants) within 14 days prior to the first study drug&#xD;
             administration and until the EOS assessments.&#xD;
&#xD;
         21. Inability to refrain from vaccinations within 14 days of the first dose of IP and&#xD;
             until the EOS assessments.&#xD;
&#xD;
         22. History of allergy or intolerance to any IP or IP constituents used on study or any&#xD;
             clinically significant drug allergy as per the PIs judgment.&#xD;
&#xD;
         23. History of anaphylaxis or other severe allergic reaction to drug, food, toxin, or&#xD;
             other exposure.&#xD;
&#xD;
         24. Any surgical or medical condition that could interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the IP.&#xD;
&#xD;
         25. Any evidence of cardiac disease or clinically significant abnormalities on ECG.&#xD;
&#xD;
         26. Systolic blood pressure (BP) &gt; 150 mmHg or &lt; 80 mmHg or diastolic BP &gt; 90 mmHg or &lt; 50&#xD;
             mmHg at Screening with one repeat allowed per the PIs discretion at Screening and Day&#xD;
             -1.&#xD;
&#xD;
         27. Heart rate &lt; 40 bpm or &gt; 100 bpm at Screening with one repeat allowed per the PIs&#xD;
             discretion at Screening and Day -1.&#xD;
&#xD;
         28. Diets that could alter metabolism (i.e., high protein, Slim Fast®, Nutrisystem®, etc.)&#xD;
             within 7 days prior to dosing on Day 1.&#xD;
&#xD;
         29. Weight loss or gain of ≥ 10% in the 30 days prior to dosing.&#xD;
&#xD;
         30. Strenuous exercise, including weightlifting, (&gt; 5 × per week) within 2 weeks prior to&#xD;
             first IP administration on Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristi McLendon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

